Trials / Completed
CompletedNCT02867397
Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors
A Phase 1, Open-Label, Non-Randomized, Dose-Finding, Safety and Tolerability Study of Orally Administered Teysuno (S-1) in Combination With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Disphar International B.V. · Industry
- Sex
- —
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of the current study was to investigate the safety and determine the maximum tolerated dose (MTD) of S-1 in combination with oxaliplatin and epirubicin in patients with advanced or metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teysuno (S1) in combination with epirubicin and oxaliplatin |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2016-08-15
- Last updated
- 2016-08-15
Source: ClinicalTrials.gov record NCT02867397. Inclusion in this directory is not an endorsement.